IBB News and Press, iShares Biotechnology ETF From 04/21/23

2023-04-21 11:13:41 ET Summary We believe the M&A wave in the biotech sector presents a prime opportunity for investors to profit from the rising valuations of small and mid-cap firms in SPDR® S&P Biotech ETF. Big pharma companies, facing patent cliffs and pricing pre...

2023-04-19 17:54:02 ET Summary We maintain a buy rating on Axsome Therapeutics, Inc.: despite potential clinical/regulatory risks, Axsome's solid cash runway and Auvelity's initial launch progress support a positive outlook. The key catalysts in the near future include data from P...

2023-04-19 14:13:51 ET Summary SPDR® S&P Biotech ETF, the Biotechnology Select Industry Index ETF, has an extreme short interest of 51.16%. XBI is in an uptrend since May-June 2022. Direxion Daily S&P Biotech Bull 3X Shares ETF, the 3X leveraged Biotech ETF, is ra...

2023-04-19 12:15:34 ET BlackRock does not expect the Federal Reserve to cut rates in 2023 despite some degree of optimism in the market. As a result, the firm warned of potential volatility during the rest of the year, advising investors to consider a more "granular" approach to equities. ...

2023-04-18 19:01:14 ET Summary Galecto (GLTO) is a clinical-stage biopharmaceutical company focused on small-molecule antifibrotic and anticancer agents. GLTO has upcoming data readouts in 2023 that could add more evidence to the potential of their therapies, including top-line IP...

2023-04-18 01:41:44 ET Summary Morphic Holding is developing innovative oral integrin therapies with lead candidate MORF-057 in phase 2. MORF-057 targets α4β7, a highly validated mechanism of action similar to Entyvio, which generated ~4$Bn in sales during 2021. ...

2023-04-17 10:30:00 ET Summary The joint stock-bond rally this year has put renewed focus on portfolio construction approaches. We think a new macro regime needs a new approach. U.S. stocks rose last week but lost steam on Friday on the market partly pricing out potential rate cut...

2023-04-16 14:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-04-16 01:22:24 ET Summary Regeneron's Dupixent reported a 30% reduction in COPD exacerbation at week 52, while ensifentrine reported a 36% and 42% reduction in the ENHANCE-1 and ENHANCE-2 trials, respectively. Ensifentrine's broader inclusion criteria and lower cost as a smal...

2023-04-13 08:01:47 ET Summary MorphoSys completed enrollment for MANIFEST-2, a Phase 3 study exploring the safety and efficacy of pelabresib in combination with ruxolitinib for JAK inhibitor-naïve patients with myelofibrosis. The topline data of the MANIFEST-2 is expected by...